Jonathan Corren, MD; Linda Rogers, MD
Jointly provided by Postgraduate Institute for Medicine and Integritas Communications
This activity is supported by an independent educational grant from AstraZeneca.
Estimated time to complete activity:
Jonathan Corren, MD
Associate Clinical Professor of Medicine and Pediatrics
David Geffen School of Medicine
University of California, Los Angeles
Medical Director, Jonathan Corren M.D. and Associates
Los Angeles, California
Linda Rogers, MD
Associate Professor of Medicine
Icahn School of Medicine and National Jewish Health
Director, Adult Asthma Program, Mount Sinai-National Jewish Health Respiratory Institute
New York, New York
This educational activity will provide insight into the underlying pathophysiology of various asthma phenotypes and their associated endotypes, the mechanistic and clinical profiles of current and emerging biologic therapies that target specific disease endotypes, and finally, how this evolving evidence can be utilized to support the practice of precision medicine within the management of severe asthma.
This activity is intended for clinical immunologists/allergists, pulmonologists, and other specialist physicians who manage patients with severe asthma.
After completing this activity, the participant should be better able to:
- Describe clinically relevant inflammatory processes involved in severe asthma pathophysiology, including implications for disease phenotyping and treatment choices
- Discuss the mechanisms of action and clinical profiles of current and emerging biologic therapies for severe asthma
- Individualize treatment regimens for patients with severe asthma based on symptoms, biomarker testing, phenotypes, and patient preferences
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
Jonathan Corren, MD: Consulting Fees: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC; Fees for Non-CME/CE Services: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC; Contracted Research: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
Linda Rogers, MD: Consulting Fees: AstraZeneca plc, Genentech, Inc., sanofi-aventis U.S. LLC; Contracted Research: AstraZeneca plc, sanofi-aventis U.S. LLC
Planners and Managers : The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers, Celeste Collazo, MD, and Jim Kappler, PhD, have nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. PIM and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions to Receive Credit
In order to received credit, participants must complete the following:
- Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
- Complete the Preactivity Questions.
- Review the activity content.
- Complete the Postactivity Test Questions and Evaluation.
- Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation to receive credit.
Microsoft Windows 2000 SE or above.
Internet Explorer (v5.5 or greater), Chrome or Firefox
MAC OS 10.2.8
Internet Explorer is not supported on the Macintosh.
PIM Contact Information
For information about the accreditation of this program, please contact PIM via e-mail at email@example.com or visit www.pimed.com
Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.Begin Activity
credit amount 0.50
credit type CME/CE
Mechanistic Insights and Emerging Treatment Options